Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of KalVista Pharmaceuticals, Inc. from 30 Apr 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
KalVista Pharmaceuticals, Inc. quarterly and annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 30 Apr 2017 to 30 Sep 2025.
  • KalVista Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2025 was $47,325,000, a 21% decline year-over-year.
  • KalVista Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending 30 Sep 2025 was $205,789,000.
  • KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $180,052,000, a 42% decline from 2023.
  • KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $126,644,000, a 36% decline from 2022.
  • KalVista Pharmaceuticals, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $92,907,000, a 13% decline from 2021.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)

KalVista Pharmaceuticals, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $205,789,000 $47,325,000 -$8,241,000 -21% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $197,548,000 $57,939,000 -$17,496,000 -43% 01 May 2025 31 Jul 2025 10-Q 11 Sep 2025 2026 Q1
Q1 2025 $180,052,000 $56,263,000 01 Feb 2025 30 Apr 2025 10-K 10 Jul 2025 2025 FY
Q4 2024 $44,262,000 -$15,234,000 -52% 01 Nov 2024 31 Jan 2025 10-Q 12 Mar 2025 2025 Q3
Q3 2024 $39,084,000 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $40,443,000 01 May 2024 31 Jul 2024 10-Q 11 Sep 2025 2026 Q1
Q4 2023 $29,028,000 01 Nov 2023 31 Jan 2024 10-Q 12 Mar 2025 2025 Q3

KalVista Pharmaceuticals, Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $180,052,000 -$53,408,000 -42% 01 May 2024 30 Apr 2025 10-K 10 Jul 2025 2025 FY
2023 $126,644,000 -$33,737,000 -36% 01 May 2023 30 Apr 2024 10-K 10 Jul 2025 2025 FY
2022 $92,907,000 -$10,568,000 -13% 01 May 2022 30 Apr 2023 10-K 11 Jul 2024 2024 FY
2021 $82,339,000 $0 0% 01 May 2021 30 Apr 2022 10-K 11 Jul 2024 2024 FY
2020 $82,339,000 -$53,099,000 -182% 01 May 2020 30 Apr 2021 10-K 11 Jul 2024 2024 FY
2019 $29,240,000 -$8,548,000 -41% 01 May 2019 30 Apr 2020 10-K 07 Jul 2022 2022 FY
2018 $20,692,000 -$4,887,000 -31% 01 May 2018 30 Apr 2019 10-K 13 Jul 2021 2021 FY
2017 $15,805,000 +$2,798,000 +15% 01 May 2017 30 Apr 2018 10-K 01 Jul 2020 2020 FY
2016 $18,603,000 01 May 2016 30 Apr 2017 10-K 16 Jul 2019 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.